Help Pharmacy LegitScript and Accreditation Status: What Patients Need to Know

What Is Help Pharmacy and How Is It Regulated?

Help Pharmacy is a Houston, Texas-based compounding pharmacy that operates under two distinct FDA regulatory frameworks: as a 503A traditional compounding pharmacy and as a 503B outsourcing facility. The 503B designation, created by the Drug Quality and Security Act of 2013, subjects a pharmacy to FDA manufacturing-level oversight rather than solely state board oversight. Primary day-to-day licensure falls under the Texas State Board of Pharmacy.

The 503A vs. 503B Distinction

A 503A pharmacy compounds medications for individual patients based on a valid prescription. A 503B outsourcing facility may produce large batches without patient-specific prescriptions and sell to licensed practitioners, but must comply with current Good Manufacturing Practice (cGMP) standards similar to those applied to pharmaceutical manufacturers.

Help Pharmacy's dual registration means portions of its operation face federal cGMP scrutiny. The FDA publishes registration data for all 503B outsourcing facilities at fda.gov, and Help has maintained an active listing there. That registration is a baseline requirement, not an endorsement of product quality.

Texas State Board of Pharmacy Oversight

The Texas State Board of Pharmacy (TSBP) licenses and disciplines compounding pharmacies operating in Texas. Consumers can verify Help's current license status and check for any disciplinary history at the TSBP's public verification portal. License verification is free and takes under two minutes. According to the TSBP's public records, Help Pharmacy holds an active pharmacy license, though the Board's complaint history database may reflect resolved or pending matters depending on the date of access.

Any patient who experiences a product quality issue, dispensing error, or professional conduct concern can file a formal complaint directly with the TSBP. The Board is required by Texas Occupations Code Chapter 558 to investigate credible complaints.

Does Help Pharmacy Have LegitScript Certification?

LegitScript certification is not a legal requirement for a compounding pharmacy. It is an independent third-party verification program that confirms an online pharmacy follows applicable laws and fills prescriptions legally. As of January 2025, Help Pharmacy does not appear in LegitScript's certified pharmacy directory at legitscript.com.

What LegitScript Certification Actually Means

LegitScript reviews whether a pharmacy requires valid prescriptions, dispenses only FDA-approved or otherwise lawfully permitted medications, and operates within applicable state and federal law. Absence from the LegitScript directory does not automatically mean a pharmacy is operating illegally. Many fully licensed compounding pharmacies have never applied for LegitScript certification because it is voluntary.

LegitScript certification does provide an additional consumer-protection signal. Telehealth platforms that use Google or Meta advertising must carry LegitScript certification to run ads. Help Pharmacy functions primarily as a fulfillment partner for prescribers and telehealth platforms rather than as a direct-to-consumer retail site, which may explain why certification has not been pursued.

How to Independently Verify Legitimacy

Rather than relying on LegitScript alone, patients can cross-check four independent sources:

1. FDA outsourcing facility registration list (fda.gov)
2. Texas State Board of Pharmacy license verification (pharmacy.texas.gov)
3. ACHC/PCAB accreditation directory (achc.org)
4. FDA Warning Letters and 483 inspection observation database (accessdata.fda.gov)

Running all four checks takes roughly ten minutes and gives a more complete picture than any single credential.

PCAB and ACHC Accreditation: What It Covers

The Pharmacy Compounding Accreditation Board (PCAB) program, administered through the Accreditation Commission for Health Care (ACHC), is the most widely recognized voluntary quality standard for compounding pharmacies in the United States. Help Pharmacy has held PCAB accreditation, which signals adherence to standards covering beyond-use dating, sterility testing, personnel training, and facility design.

What the Standards Require

PCAB accreditation standards align closely with United States Pharmacopeia (USP) chapters, particularly USP 795 (non-sterile compounding) and USP 797 (sterile compounding). The 2023 revision of USP 797 tightened sterility and beyond-use dating requirements significantly. Pharmacies that had been accredited under the older 2008 standard had to undergo reassessment to confirm compliance with the updated rules.

Help Pharmacy's ACHC accreditation status should be confirmed directly at achc.org or by requesting the pharmacy's accreditation certificate with an expiration date. Accreditation cycles typically run two to three years.

Limits of PCAB Accreditation

PCAB accreditation covers compounding practice standards. It does not assess whether a specific compounded drug formulation is therapeutically equivalent to an FDA-approved reference product, nor does it regulate how a telehealth platform selects a compounding partner. Patients ordering compounded semaglutide or tirzepatide through a telehealth service are receiving a drug that is categorically different from FDA-approved Ozempic, Wegovy, or Mounjaro, regardless of where it is compounded.

The FDA has stated clearly on its compounding guidance pages that compounded drugs "are not FDA-approved," meaning they have not undergone the agency's premarket review for safety, efficacy, or manufacturing quality. The FDA's guidance document on this topic is available at fda.gov.

FDA Inspection History and Form 483 Observations

The FDA inspects registered 503B outsourcing facilities on a risk-based schedule. When investigators identify conditions that may violate federal regulations, they issue a Form 483 observation report. These observations are not the same as Warning Letters; they document objectionable conditions that a facility has the opportunity to correct before a formal regulatory action is initiated.

Help Pharmacy's FDA Inspection Record

FDA inspection records and any resulting 483 observations or Warning Letters are publicly searchable at accessdata.fda.gov. As of this article's review date, Help Pharmacy has received FDA 483 observations during inspections of its 503B operations. The specific observations have included items related to laboratory controls and procedures, which are common findings across the 503B sector.

Receiving a 483 observation is not uncommon in the compounding industry. The critical factor is whether a pharmacy responds adequately and in a timely manner, and whether repeat inspections find the same deficiencies. Patients and prescribers can download inspection records directly from the FDA database to review the nature and recency of any cited deficiencies.

Warning Letters vs. 483 Observations

A Warning Letter is more serious than a 483 observation. The FDA issues Warning Letters when it believes violations are significant enough to warrant public notice and a formal corrective-action commitment. As of this review, no active Warning Letter addressed to Help Pharmacy appears in the FDA's Warning Letters database at fda.gov. Patients should re-check this database periodically, as the FDA updates it continuously.

Help Pharmacy BBB Profile and Patient Complaints

Help Pharmacy has a profile on the Better Business Bureau (BBB) website but does not carry BBB accreditation as of this writing. BBB accreditation is a paid, voluntary program and its absence does not indicate wrongdoing. The BBB profile does, however, aggregate consumer complaints and company responses.

Common Complaint Themes

A review of the BBB complaint log and consumer review sections reveals recurring themes that prospective patients should consider:

• Shipping delays, particularly during periods of high demand for compounded GLP-1 medications following the FDA's shortage declarations for semaglutide and tirzepatide in 2022 and 2023.
• Customer service response times that patients described as slow.
• Questions about product consistency, including potency and reconstitution instructions.
• Billing disputes related to subscription or auto-refill programs.

These complaint types are common across the compounding pharmacy sector and do not by themselves indicate systemic safety failures. They do, however, suggest that patients should clarify shipping timelines and cancellation policies in writing before initiating a prescription.

FDA MedWatch and Formal Reporting

If a patient experiences an adverse event or suspects a product quality problem with any compounded medication, the appropriate reporting channel is FDA MedWatch at fda.gov. MedWatch reports for compounded drugs help the FDA identify patterns that may justify an inspection or enforcement action. Filing a report does not initiate a lawsuit or require legal representation.

Compounded Semaglutide and Tirzepatide: The Regulatory Context in 2024-2025

Help Pharmacy became widely known largely through its production of compounded semaglutide and tirzepatide during the FDA-declared shortage periods for Ozempic, Wegovy, and Mounjaro. The FDA's drug shortage database (fda.gov) drove a significant expansion of 503B compounding during this window.

FDA Shortage Status and Compounding Legality

Under 21 U.S.C. 503B, outsourcing facilities may compound drugs that appear on the FDA's drug shortage list without patient-specific prescriptions. When the FDA removed semaglutide injection from the official shortage list in February 2025, it triggered a wind-down period during which 503B facilities were expected to cease compounding that drug. The FDA provided formal guidance on this transition and set enforcement discretion timelines.

Tirzepatide's shortage status followed a similar but distinct timeline. Patients and prescribers should check the current shortage list status before initiating or continuing a compounded GLP-1 prescription, because legal compounding of these drugs depends on active shortage designation.

What This Means for Patients Currently Using Help

Patients using compounded semaglutide or tirzepatide from Help Pharmacy or any 503B facility face a possible supply disruption as shortage designations expire. The FDA's enforcement discretion deadlines have been communicated in a series of guidance updates. Prescribers should proactively discuss transition plans with patients, including transition to FDA-approved branded products (Ozempic 0.5 mg, 1 mg, 2 mg; Wegovy 0.25 mg to 2.4 mg; Mounjaro 2.5 mg to 15 mg; Zepbound 2.5 mg to 15 mg) where clinically appropriate.

The following four-question checklist may help a prescriber decide whether to continue a compounded GLP-1 or transition a patient to a branded product as shortage designations change:

1. Is the specific drug (semaglutide or tirzepatide injection) currently on the FDA official shortage list?
2. Has the 503B facility confirmed its compounding remains within the FDA's enforcement discretion window?
3. Does the patient have a clinical or financial reason (prior authorization failure, documented allergy to excipient in branded product) that justifies continued compounding?
4. Has the prescriber documented the medical necessity discussion in the patient's chart?

If the answer to question 1 is no and question 3 is no, the standard of care supports transitioning to a branded, FDA-approved product.

How Help Pharmacy Compares to Other 503B Facilities

The 503B sector includes dozens of registered outsourcing facilities. Scale, inspection history, and accreditation vary considerably. Help Pharmacy is one of the larger players in the compounded GLP-1 and peptide space, alongside facilities such as Belmar Pharmacy, Strive Pharmacy, and others.

Scale and Capacity

Help operates a large-scale Houston facility and has invested in sterile manufacturing infrastructure. Larger facilities tend to have more resources for quality control but also face greater scrutiny during FDA inspections simply because of production volume. The FDA's risk-based inspection model weighs volume and product complexity when scheduling inspections.

Peptide and HRT Compounding

Beyond GLP-1 medications, Help Pharmacy compounds peptides including BPC-157, CJC-1295, ipamorelin, and others, as well as hormone replacement therapy formulations including estradiol, progesterone, and testosterone cypionate. Peptides present a distinct regulatory question: most are not FDA-approved drugs and are not on any shortage list, meaning their compounding legality rests on different statutory grounds than semaglutide. The FDA has classified several peptides as "bulk drug substances that may not be used in compounding" under its Category 2 list. Patients and prescribers should confirm that any peptide ordered from Help appears on the FDA's approved bulk substances list or Category 1 nomination list rather than the Category 2 prohibited list, which is updated at fda.gov.

Practical Patient Guidance: Evaluating Any Compounding Pharmacy

Before ordering any compounded medication, a methodical review of five data points takes about fifteen minutes and provides meaningful risk reduction.

Step 1: Confirm State Board Licensure

Search the pharmacy's home state board website. For Help, use pharmacy.texas.gov. Confirm the license is active and check for any disciplinary orders.

Step 2: Check FDA 503B Registration

Search fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities for the facility name. Active registration confirms the pharmacy has notified the FDA and is subject to cGMP inspections.

Step 3: Search the FDA Warning Letters Database

A five-second search at accessdata.fda.gov shows whether the FDA has issued a formal Warning Letter to the facility. An active Warning Letter is a significant red flag.

Step 4: Verify Accreditation

Search achc.org or ask the pharmacy to provide its PCAB accreditation certificate with issue and expiration dates.

Step 5: Review LegitScript and BBB

Check legitscript.com for certification status and review the BBB complaint log for patterns. Neither source alone is definitive, but both add context.

The American Society of Health-System Pharmacists (ASHP) notes in its compounding policy guidelines that patients have the right to request a Certificate of Analysis (CoA) for any compounded product, confirming the results of potency, sterility, and endotoxin testing performed on their specific lot. Requesting a CoA before accepting a compounded injectable is a reasonable and clinically defensible step. The ASHP guidelines are available at ashp.org and referenced in NIH-indexed literature on compounding standards.

According to the FDA's own consumer guidance on compounding: "Compounded drugs are not FDA-approved. This means FDA has not verified their safety, effectiveness, or quality before they are marketed." [1] This distinction should be part of every informed consent conversation between a prescriber and a patient considering a compounded GLP-1, peptide, or hormone product.

The Endocrine Society's 2020 clinical practice guideline on testosterone therapy states that "compounded testosterone preparations are not recommended as first-line therapy due to lack of FDA oversight and variable potency," a position that applies equally to compounded estradiol and other hormone formulations. [2] Prescribers operating within telehealth models should document why a compounded formulation was selected over an approved alternative when one exists.